These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 33907839)

  • 1. Role of 2‑series prostaglandins in the pathogenesis of type 2 diabetes mellitus and non‑alcoholic fatty liver disease (Review).
    Wang W; Zhong X; Guo J
    Int J Mol Med; 2021 Jun; 47(6):. PubMed ID: 33907839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mori Cortex extract ameliorates nonalcoholic fatty liver disease (NAFLD) and insulin resistance in high-fat-diet/streptozotocin-induced type 2 diabetes in rats.
    Ma LL; Yuan YY; Zhao M; Zhou XR; Jehangir T; Wang FY; Xi Y; Bu SZ
    Chin J Nat Med; 2018 Jun; 16(6):411-417. PubMed ID: 30047462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NAFLD and diabetes mellitus.
    Tilg H; Moschen AR; Roden M
    Nat Rev Gastroenterol Hepatol; 2017 Jan; 14(1):32-42. PubMed ID: 27729660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential patterns of insulin secretion and sensitivity in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease versus patients with type 2 diabetes mellitus alone.
    Chai SY; Pan XY; Song KX; Huang YY; Li F; Cheng XY; Qu S
    Lipids Health Dis; 2014 Jan; 13():7. PubMed ID: 24397589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Sesquiterpene Glycoside from Loquat Leaf Alleviates Type 2 Diabetes Mellitus Combined with Nonalcoholic Fatty Liver Disease by Improving Insulin Resistance, Oxidative Stress, Inflammation, and Gut Microbiota Composition.
    Chen J; Ding X; Wu R; Tong B; Zhao L; Lv H; Meng X; Liu Y; Ren B; Li J; Jian T; Li W
    J Agric Food Chem; 2021 Dec; 69(47):14176-14191. PubMed ID: 34783554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD).
    Ortiz-Lopez C; Lomonaco R; Orsak B; Finch J; Chang Z; Kochunov VG; Hardies J; Cusi K
    Diabetes Care; 2012 Apr; 35(4):873-8. PubMed ID: 22374640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of Hepassocin in Diabetic Patients with Nonalcoholic Fatty Liver Disease May Facilitate Increased Hepatic Lipid Accumulation.
    Abdelmoemen G; Khodeir SA; Zaki AN; Kassab M; Abou-Saif S; Abd-Elsalam S
    Endocr Metab Immune Disord Drug Targets; 2019; 19(2):185-188. PubMed ID: 30009716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease.
    Lou DJ; Zhu QQ; Si XW; Guan LL; You QY; Yu ZM; Zhang AZ
    J Diabetes Complications; 2014; 28(5):711-4. PubMed ID: 24927647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic Mediators of Lipid Metabolism and Ketogenesis: Focus on Fatty Liver and Diabetes.
    Fernandes GW; Bocco BMLC
    Curr Diabetes Rev; 2021; 17(7):e110320187539. PubMed ID: 33143628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of metabolic risk factors for developing nonalcoholic fatty liver in patients with type 2 diabetes mellitus].
    Guo M; Xi G; Yang N; Yao H
    Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):631-5. PubMed ID: 25243967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus.
    Bril F; Cusi K
    Endocrinol Metab Clin North Am; 2016 Dec; 45(4):765-781. PubMed ID: 27823604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic liver disease in diabetes - From mechanisms to clinical trials.
    Dewidar B; Kahl S; Pafili K; Roden M
    Metabolism; 2020 Oct; 111S():154299. PubMed ID: 32569680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease.
    Fujii H; Kawada N; Japan Study Group Of Nafld Jsg-Nafld
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32485838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes.
    Markova M; Pivovarova O; Hornemann S; Sucher S; Frahnow T; Wegner K; Machann J; Petzke KJ; Hierholzer J; Lichtinghagen R; Herder C; Carstensen-Kirberg M; Roden M; Rudovich N; Klaus S; Thomann R; Schneeweiss R; Rohn S; Pfeiffer AF
    Gastroenterology; 2017 Feb; 152(3):571-585.e8. PubMed ID: 27765690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
    Asrih M; Jornayvaz FR
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD).
    Tanase DM; Gosav EM; Costea CF; Ciocoiu M; Lacatusu CM; Maranduca MA; Ouatu A; Floria M
    J Diabetes Res; 2020; 2020():3920196. PubMed ID: 32832560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic Targets in Nonalcoholic Fatty Liver Disease.
    Esler WP; Bence KK
    Cell Mol Gastroenterol Hepatol; 2019; 8(2):247-267. PubMed ID: 31004828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance?
    Shabani P; Naeimi Khaledi H; Beigy M; Emamgholipour S; Parvaz E; Poustchi H; Doosti M
    PLoS One; 2015; 10(3):e0118650. PubMed ID: 25767880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
    Liu X; Chen S; Zhang L
    Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.